

11-03-2009

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office



SHEET

Y Attorney Docket No.: 2488-1-015PCT/US

103579453

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)/Execution Date(s):

EVOLUTEC LIMITED

Execution Date(s) September 5, 2007

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other _____

2. Name and address of receiving party(ies)

Name: VARLEIGH LIMITED

Internal Address: _____

Street Address: Whiteley Chambers

Don Street

City: St Helier

State: Jersey

Country: Great Britain Zip: JE4 9WG

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

11/991,690

(371 National Phase Entry of PCT/GB2006/003265)

B. Patent No.(s)

NOV - 2

Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Sarah J. Fashena, Ph.D.

Internal Address: _____

Street Address: KLAUBER & JACKSON LLC

411 HACKENSACK AVE., 4TH FLOOR

City: HACKENSACK

State: NJ Zip: 07601

Phone Number: 201-487-5800

Fax Number: 201-343-1684

Email Address: Info@KJIPLAW.COM

6. Total number of applications and patents involved:

1

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00

- ☐ Authorized to be charged by credit card
☐ Authorized to be charged to deposit account
☒ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers _____

Expiration Date _____

b. Deposit Account Number _____

11/02/2009 MIAMI 00000030 11991690
Authorized User Name
01 FC:0021

9. Signature:

Sarah J. Fashena
Signature

Sarah J. Fashena, Ph.D., Reg. No. 57,600

Name of Person Signing

October 27, 2009

Date

Total number of pages including cover sheet, attachments, and documents:

14

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

PATENT
REEL: 023460 FRAME: 0156

THIS ASSIGNMENT is dated

5th September

2007

BETWEEN:

- (1) **EVOLUTEC LIMITED** (Registered Number 03578152), whose registered office is at 3 More London Riverside, London SE1 2AQ (the "Assignor"); and
- (2) **VARLEIGH LIMITED** a company incorporated in Jersey under Registered Number 82766 whose registered office is at Whiteley Chambers, Don Street, St Helier, Jersey JE4 9WG (the "Assignee").

WHEREAS:

- (A) The Assignor is the owner and is entitled to be registered as the proprietor of the patents or of the applications for the grant of patents, short particulars of which are set out in the Appendix (the "Patents"); and
- (B) Pursuant to an Asset Purchase Agreement dated on or about the date of this Assignment between the parties the Assignor has agreed to assign all its rights, title and interest in and to the Patents to the Assignee for the consideration mentioned below.

NOW IT IS HEREBY AGREED as follows:


- 1 In consideration of the payment by the Assignee to the Assignor of  (receipt of which is hereby acknowledged) the Assignor HEREBY ASSIGNS to the Assignee all its rights, title and interest in and to the Patents including the benefit of the applications for registration with the intention that if the applications are granted the registration will vest in the Assignee and any common law rights and all the goodwill attaching to the Patents.
- 2 This Assignment shall include the right for the Assignee to bring proceedings against any third party in respect of the Patents (including proceedings against any third party for infringement of the Patents or for passing off or for otherwise infringing the rights in the Patents whether taking place before or after the date of this Assignment).
- 3 This Assignment shall be governed by and construed in accordance with English law and the parties irrevocably agree that the courts of England are to have exclusive jurisdiction to any disputes which arise out of or in connection with this Assignment.

IN WITNESS WHEREOF this Assignment has been entered into on the day and year first above written.

SIGNED by
for and on behalf of
Evolutec Limited

)
)
)
)
)

SIGNED by
for and on behalf of
Varleigh Limited

)
)
)
)

S.M.J. Ford
Director

SIGNED by
for and on behalf of
Evolutec Limited

)
)
)
)
) *David Bloxham*
) DR DAVID PHILIP BLOXHAM

SIGNED by
for and on behalf of
Varleigh Limited

)
)
)
)
)

Patents and patent applications

1. CASES RELATING TO VASOACTIVE AMINE BINDING MOLECULES

- 1.1 Initial vasoactive amine binding molecules application (C&R ref: P017168)
 - First disclosure of FS-HBP2 (EV131), FS-HBP1, MS-HBP1 and D.RET6 (EV598).

Applicant	Title	Application number	Filing date	Priority dates	Expiry date of any patents granted	Inventors
Evotec Limited	Vasoactive amine binding molecules	PCT/GB97/01372	19/05/97	18/05/96 GB 9610484.9 (National Environmental Research Council) 18/4/97 GB 9707844.8 (Oxford Vacs Ltd.)	19/05/17	NUTTALL, Patricia Anne (CEH) PAESEN, Guido Christiaan (CEH)

Country	Application/Grant No.	Status
Europe	906425	Granted
United States of America	6617312	Granted
Australia	725630	Granted
Brazil	PI 9709101.4	Pending.
Canada	2253924	Pending.
China	1198927	Granted
Cuba	23164	Granted
Hong Kong	1019158	Granted
Japan	9-541799	Pending
Mexico	230912	Granted
New Zealand	332648	Granted

CFD-#5429727-v1

1.2 Histamine and serotonin binding molecules (C&R ref: P018367)

Disclosure of binding sites of FS-HBP2 (EV131), FS-HBP1, MS-HBP1 and D.RET6 (EV598).

Applicant	Title	Application number	Filing date	Priority dates	Date of expiry of any patents	Inventors
Evolutec Ltd	Histamine binding molecules	PCT/GB98/03530	26/11/98	26/11/97 GB 9725046.8 (National Environmental Research Council) 26/6/98 GB 9813917.3 (National Environmental Research Council)	26/11/18	NUTTALL, Patricia Anne (CEH) PAESEN, Guido Christiaan (CEH)

Country	Application No.	Status
Europe	98955786.3	Abandoned
United States of America	09/555,296	Abandoned
Australia	763299	Granted
Brazil	PI9815056-1	Pending
Canada	2309809	Pending
China	98813321.0	Pending
Cuba	121/2000	Abandoned
Czech Republic	PV2000-1927	Pending
Hong Kong	00106487.7	Abandoned
Japan	2000-522246	Pending
Mexico	5010	Abandoned
New Zealand	504753	Granted
Poland	P-340728	Abandoned.
Slovak Republic	PV0791-2000	Pending

CFD-#5429727-v1

1.3 Treatment of allergic rhinitis (C&R ref: P022734)

- Use of FS-HBP2 (EV131), MS-HBP1 and FS-HBP1 in the treatment of allergic rhinitis.

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Treatment of allergic rhinitis	PCT/GB00/03287	24/08/00	1/09/99 GB 9920673.2 (Evolutec Ltd)	24/08/20	NUTTALL, Patricia Anne (CEH) PAESEN, Guido Christiaan (CEH)

Country	Application No.	Status
Europe	1207899	Granted
United States of America	6,794,360	Granted
Australia	778514	Granted
Brazil	P10013655-7	Pending
Canada	2382570	Pending
China	00812372.1	Pending
Japan	2001-519725	Pending
Mexico	PA/a/2002/02044	Granted
New Zealand	517765	Granted
Hong Kong	1043541	Granted

1.4 Treatment of conjunctivitis (C&R ref: P022735)

- Use of FS-HBP2 (EV131), MS-HBP1 and FS-HBP1 in the treatment of allergic conjunctivitis

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Treatment of conjunctivitis	PCT/GB00/03282	24/08/00	1/09/99 GB 9920674.0 (Evolutec Ltd)	24/08/20	NUTTALL, Patricia Anne (CEH) PAESEN, Guido Christiaan (CEH)

CFD-#5429727-v1

Country	Application No.	Status
Europe	1207898	Granted
United States of America	6,737,399	Granted
Australia	780773	Granted
Brazil	P10013665-4	Pending
Canada	2382473	Pending
China	00814774.4	Pending
Cuba	37/2002	Abandoned
Japan	2001-519931	Pending
Mexico	PA/a/2002/01807	Granted
New Zealand	517218	Granted
Hong Kong	1046362	Granted

1.5 Treatment method for disease conditions mediated by neutrophils (C&R ref: P033714)
- Methods of treating disease conditions mediated by neutrophils (e.g. ARDS) using FS-HBP2 (EV131), MS-HBP1 and FS-HBP1

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Treatment method for disease conditions mediated by neutrophils	PCT/GB2004/001428	01/04/04	01/04/03 GB 0307544.7 (Evolutec Limited)	01/04/24	Wynne WESTON-DAVIES (Evolutec)

Country	Application No.	Status
Europe	04725105.3	Pending
United States of America	10/551482	Pending
Australia	2004226697	Pending
Brazil	P10408984-7	Pending
Canada	2,520,580	Pending
China	200480014569.8	Pending
Japan	2006-506075	Pending
Mexico	2005/010480	Pending
New Zealand	542831	Pending
Hong Kong	06104219.1	Pending

CFD-#5429727-v1

1.6 Histamine binding protein applications (C&R ref: P044141GB, P044846GB and P044842US)

- Discloses "mutant" EV131 sequence.

Country	Applicant	Title	Application number	Filing date	Inventors	Status
Great Britain	Evolutec Limited	Histamine Binding protein	0611579.4	12/06/06		Abandoned
Great Britain	Evolutec Limited	Histamine Binding protein	0617948.5	12/09/06		Pending
United States	Evolutec Limited	Histamine Binding protein	60/898911	01/02/07	PAESEN, Guido Christiaan (CEH) Wynne WESTON-DAVIES (Evolutec)	Pending

2. Complement inhibitor applications:

2.1 Initial Complement inhibitor application (C&R ref: P034332)

- Discloses OmCI protein (EV576) and various applications

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Complement inhibitors	PCT/GB2004/002341	02/06/04	02/06/03 GB 0312619.0 (Evolutec Limited) 25/11/03 GB 0327386.9 (Evolutec Limited)	02/06/24	Miles Andrew NUNN (CEH)

CFD-#5429727-v1

Country	Application No.	Status
Europe	04735758.7	Pending
United States of America	10/558937	Pending
Australia	2004242759	Pending
Brazil	P10410876-0	Pending
Canada	2526083	Pending
China	200480015178.8	Pending
Cuba	2005-0248	Abandoned
Japan	2006-508396	Pending
Mexico	PA/A/2005/12880	Pending
New Zealand	544163	Pending
Hong Kong	06105580.9	Pending

2.2 Treatment of myasthenia gravis (our ref: P041905WO):

- EV576 in treatment of myasthenia gravis - pending in international phase

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors	Status
Evolutec Limited	Treatment of myasthenia gravis	PCT/GB2006/003265	05/09/06	09/09/05 GB 0518443.7 (Evolutec Limited)	05/09/26	WESTON-DAVIES, Wynne HAMER, John	Pending

2.3 Treatment of peripheral nerve disorders (our ref: P044809GB):

- EV576 in the treatment of peripheral nerve disorders

Country	Applicant	Title	Application number	Filing date	Status
Great Britain	Evolutec Limited	Treatment of peripheral nerve disorders	0617734.9	08/09/06	Pending

CFD-#5429727-V1

2.4 Treatment of respiratory disorders (our ref: P044811GB & P045456US):

- EV576 in the treatment of respiratory disorders

Country	Applicant	Title	Application number	Filing date	Inventors	Status
Great Britain	Evolutec Limited	Treatment of respiratory disorders	0617735.6	08/09/06		Pending
United States	Evolutec Limited	Treatment of respiratory disorders	60/860730	22/11/06	John HAMER	Pending

3. Other applications:

3.1 Inhibitor proteins (C&R ref: P022288)

- Discloses TdPI protein (EV223)

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Ltd	Inhibitor proteins	PCT/GB00/02791	19/07/00	19/07/99 GB 9916913.8 (Natural Environmental Research Council)	19/07/20	NUTTALL, Patricia Anne (CEH) PAESEN, Guido Christiaan (CEH)

Country	Application No.	Status
Europe	00946166.6	Granted
United States of America	6,987,168	Granted
Australia	781498	Granted
Canada	2379627	Pending
China	00812774.3	Pending

CFD-#5429727-v1

Japan	2001-511480	Pending
Mexico	PA/a/2002/00677	Granted
New Zealand	516809	Granted
Hong Kong	02103668.3	Pending

3.2 Screening method (C&R ref: P023661)

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Screening method	PCT/GB00/05001	22/12/00	23/12/99 GB-9930564.1	22/12/2020	NUTALL, Patricia Anne (CEH)

Country	Application No.	Status
Europe	1247102	Granted
United States of America	10/178912	Pending
Canada	2397273	Pending
Hong Kong	1047791	Granted

CFD-#5429727-v1

3.3 Regulator molecules (C&R ref: P023927)

- No complete sequences disclosed. Just fractions having activity.

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Regulator molecules	PCT/GB01/00536	09/02/01	11/02/00 GB 0003245.8 (Evolutec Ltd)	09/02/21	Norbert FUCHSBERGER Valeria HAJNICKA Paula KOCAKOVA Mirko SLOVAK Juraj GASPERIK

Country	Application No.	Status
Europe	01904133.4	Pending
United States of America	10/217342	Pending

CFD-#5429727-v1

3.4 Ion channel modulators (C&R ref: P027525)

- Discloses EV048 sequence

Applicant	Title	Application number	Filing date	Priority date	Expiry date of any patents	Inventors
Evolutec Limited	Ion channel modulators	PCT/GB02/02919	21/06/02	22/06/01 GB 0115363.4 (Evolutec Ltd.)	21/06/22	Petra RAJSKA Olga PECHANOVA Peter TAKAC Miles Andrew NUNN (CEH) Patricia Anne NUTTALL (CEH) Milan LABUDA Maria KAZIMIROVA Norbert VRBJAR Milan KOZANEK

Country	Application No.	Status
Europe	02748981.4	Pending
United States of America	10/743280	Abandoned.

CFD-#5429727-v1